At Arizona Oncology, we know a prostate cancer diagnosis may feel overwhelming. Our physicians are relentlessly dedicated to delivering the best care possible for each patient’s individual needs. That’s why our multidisciplinary tumor board committee includes experts in urology, medical oncology, radiation oncology, radiology, and pathology, who all work together to develop your optimal treatment plan.
We are proud to offer a leading-edge treatment for prostate cancer. It combines the use of PET scans and a new therapy targeting prostate-specific membrane antigen (PSMA)-positive cancer cells that have spread and become resistant to other forms of treatment.
Pluvicto™ is the first and only treatment that targets PSMA+ cancer cells wherever they are in the body.
PSMA is a protein on the surface of most positive prostate cancer cells. This new therapy, which was approved by the US Food and Drug Administration in March 2022, uses a tracing agent (ligand) that attaches to PSMA. If this tracer binds to the cancer cells, they light up on a PET/CT scan, and patients are then eligible for a drug called Pluvicto™. This medication is injected into the bloodstream to deliver targeted radiation to cancer cells throughout the body that express PSMA. The treatment targets bone, nodal, and visceral metastases.
Who Qualifies For Pluvicto™?
Adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:
- Has spread to other parts of the body (metastatic)
- Has already been treated with other anticancer treatments
How Does Pluvicto™ Work?
- Pluvicto™ is a targeted therapy that delivers radiation treatment directly to PSMA+ cells, including tumors.
- It is given via IV injection or infusion approximately every six weeks for up to six treatments, depending on how the patient responds.
What Kind of Results Has Pluvicto™ Produced?
Pluvicto™ has helped men live longer:
- Men with PSMA+ mCRPC who received Pluvicto™ and the best standard of care, lived a median of 4 months longer: 15.3 months vs. 11.3 months with BSoC (best standard of care) alone.*
- Men treated with Pluvicto™ plus BSoC lived longer without their cancer growing or spreading—a median of 8.7 months compared with 3.4 months when on BSoC only.**
With this treatment, the doctors at Arizona Oncology hope your prostate cancer diagnosis can feel a little less overwhelming.
Other state-of-the-art treatments for prostate cancer that we offer include:
Multiparametric MRI – This scan combines several MRI techniques into one session, providing a more comprehensive way to detect and evaluate tumors.
Prostate-specific membrane antigen (PSMA) PET-CT – A tracing agent is used during imaging to detect prostate cancer cells in the body with high specificity and sensitivity, allowing for a more accurate picture of where the cancer is located.
Hydrogel (Barrigel) rectal spacer placement – A biodegradable hydrogel is placed between the prostate and the rectum to create space and reduce radiation exposure to the rectum.
Fiducial placement – Small markers are placed in the prostate gland to help guide radiation treatment.
Stereotactic body radiation therapy (SBRT) – A highly complex, convenient and short course (five sessions) of radiation therapy to maximize effectiveness in the prostate gland while minimizingside effects to surrounding healthy tissue.
Xofigo® – This drug is injected into the bloodstream and is used to treat prostate cancer that has spread to the bone.
Medically integrated dispensing pharmacy – We fill prescriptions for Orgovyx® (relugolix), Xtandi®(enzalutamide), Zytiga® (abiraterone acetate), Erleada® (apalutamide), Nubeqa® (darolutamide).
*The Pluvicto™ clinical study measured overall survival (OS). This is the total time men with metastatic prostate cancer were alive from the start of treatment. Median OS is the length of time half of the men were still alive. In a study of 831 men with PSMA+ metastatic prostate cancer, 551 were treated with Pluvicto™ once every 6 weeks (up to 6 treatments) plus BSoC as determined by their doctor. Another 280 were treated with BSoC alone.
**The Pluvicto™ clinical study measured radiographic progression-free survival (rPFS). This is the length of time men in the study lived with PSMA+ mCRPC without it spreading or getting worse. Median rPFS is the length of time when half of the men were still alive without their cancer spreading or getting worse.